Serum 90K/MAC-2BP glycoprotein levels in hepatocellular carcinoma and cirrhosis

Mario Correale, V. Giannuzzi, P. A. Iacovazzi, M. A. Valenza, S. Lanzillotta, I. Abbate, M. Quaranta, M. L. Caruso, S. Elba, O. G. Manghisi

Research output: Contribution to journalArticle

Abstract

90K/MAC-2BP glycoprotein is a serum tumour marker, member of the scavenger receptor cysteine rich (SRCR) protein superfamily, involved in different immunological mechanisms. In the present study, we determined 90K serum levels by a sandwich enzyme immunoassay using the same monoclonal antibody in 11 chronic active hepatitis (CAH), 48 liver cirrhosis and 36 hepatocellular carcinoma (HCC). In comparison, the same samples were also tested for AFP. According to a cut-off point of 14 μg/mL for the 90K, established as 100% of specificity in 50 controls, we observed increasing positivities from CAH to cirrhosis and then to HCC (27%, 50% and 78%, respectively). In cirrhotic patients 90K levels were associated with the presence of anti-HCV antibodies, but not with the degree of liver compromise. Finally, 90K sensitivity was higher than AIFP in all groups of hepatic patients. However, further investigations are needed before proposing 90K as a clinical useful tumour marker in the progression from cirrhosis to HCC.

Original languageEnglish
Pages (from-to)3469-3472
Number of pages4
JournalAnticancer Research
Volume19
Issue number4 C
Publication statusPublished - 1999

Fingerprint

Hepatocellular Carcinoma
Glycoproteins
Fibrosis
Chronic Hepatitis
Tumor Biomarkers
Serum
Scavenger Receptors
Hepatitis C Antibodies
Liver
Immunoenzyme Techniques
Liver Cirrhosis
Cysteine
Biomarkers
Monoclonal Antibodies
Proteins

Keywords

  • 90K
  • Alpha-fetoprotein
  • Hepatocellular carcinoma
  • Tumour markers

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Correale, M., Giannuzzi, V., Iacovazzi, P. A., Valenza, M. A., Lanzillotta, S., Abbate, I., ... Manghisi, O. G. (1999). Serum 90K/MAC-2BP glycoprotein levels in hepatocellular carcinoma and cirrhosis. Anticancer Research, 19(4 C), 3469-3472.

Serum 90K/MAC-2BP glycoprotein levels in hepatocellular carcinoma and cirrhosis. / Correale, Mario; Giannuzzi, V.; Iacovazzi, P. A.; Valenza, M. A.; Lanzillotta, S.; Abbate, I.; Quaranta, M.; Caruso, M. L.; Elba, S.; Manghisi, O. G.

In: Anticancer Research, Vol. 19, No. 4 C, 1999, p. 3469-3472.

Research output: Contribution to journalArticle

Correale, M, Giannuzzi, V, Iacovazzi, PA, Valenza, MA, Lanzillotta, S, Abbate, I, Quaranta, M, Caruso, ML, Elba, S & Manghisi, OG 1999, 'Serum 90K/MAC-2BP glycoprotein levels in hepatocellular carcinoma and cirrhosis', Anticancer Research, vol. 19, no. 4 C, pp. 3469-3472.
Correale M, Giannuzzi V, Iacovazzi PA, Valenza MA, Lanzillotta S, Abbate I et al. Serum 90K/MAC-2BP glycoprotein levels in hepatocellular carcinoma and cirrhosis. Anticancer Research. 1999;19(4 C):3469-3472.
Correale, Mario ; Giannuzzi, V. ; Iacovazzi, P. A. ; Valenza, M. A. ; Lanzillotta, S. ; Abbate, I. ; Quaranta, M. ; Caruso, M. L. ; Elba, S. ; Manghisi, O. G. / Serum 90K/MAC-2BP glycoprotein levels in hepatocellular carcinoma and cirrhosis. In: Anticancer Research. 1999 ; Vol. 19, No. 4 C. pp. 3469-3472.
@article{0e49cdee06964d74b172409962b7b723,
title = "Serum 90K/MAC-2BP glycoprotein levels in hepatocellular carcinoma and cirrhosis",
abstract = "90K/MAC-2BP glycoprotein is a serum tumour marker, member of the scavenger receptor cysteine rich (SRCR) protein superfamily, involved in different immunological mechanisms. In the present study, we determined 90K serum levels by a sandwich enzyme immunoassay using the same monoclonal antibody in 11 chronic active hepatitis (CAH), 48 liver cirrhosis and 36 hepatocellular carcinoma (HCC). In comparison, the same samples were also tested for AFP. According to a cut-off point of 14 μg/mL for the 90K, established as 100{\%} of specificity in 50 controls, we observed increasing positivities from CAH to cirrhosis and then to HCC (27{\%}, 50{\%} and 78{\%}, respectively). In cirrhotic patients 90K levels were associated with the presence of anti-HCV antibodies, but not with the degree of liver compromise. Finally, 90K sensitivity was higher than AIFP in all groups of hepatic patients. However, further investigations are needed before proposing 90K as a clinical useful tumour marker in the progression from cirrhosis to HCC.",
keywords = "90K, Alpha-fetoprotein, Hepatocellular carcinoma, Tumour markers",
author = "Mario Correale and V. Giannuzzi and Iacovazzi, {P. A.} and Valenza, {M. A.} and S. Lanzillotta and I. Abbate and M. Quaranta and Caruso, {M. L.} and S. Elba and Manghisi, {O. G.}",
year = "1999",
language = "English",
volume = "19",
pages = "3469--3472",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "4 C",

}

TY - JOUR

T1 - Serum 90K/MAC-2BP glycoprotein levels in hepatocellular carcinoma and cirrhosis

AU - Correale, Mario

AU - Giannuzzi, V.

AU - Iacovazzi, P. A.

AU - Valenza, M. A.

AU - Lanzillotta, S.

AU - Abbate, I.

AU - Quaranta, M.

AU - Caruso, M. L.

AU - Elba, S.

AU - Manghisi, O. G.

PY - 1999

Y1 - 1999

N2 - 90K/MAC-2BP glycoprotein is a serum tumour marker, member of the scavenger receptor cysteine rich (SRCR) protein superfamily, involved in different immunological mechanisms. In the present study, we determined 90K serum levels by a sandwich enzyme immunoassay using the same monoclonal antibody in 11 chronic active hepatitis (CAH), 48 liver cirrhosis and 36 hepatocellular carcinoma (HCC). In comparison, the same samples were also tested for AFP. According to a cut-off point of 14 μg/mL for the 90K, established as 100% of specificity in 50 controls, we observed increasing positivities from CAH to cirrhosis and then to HCC (27%, 50% and 78%, respectively). In cirrhotic patients 90K levels were associated with the presence of anti-HCV antibodies, but not with the degree of liver compromise. Finally, 90K sensitivity was higher than AIFP in all groups of hepatic patients. However, further investigations are needed before proposing 90K as a clinical useful tumour marker in the progression from cirrhosis to HCC.

AB - 90K/MAC-2BP glycoprotein is a serum tumour marker, member of the scavenger receptor cysteine rich (SRCR) protein superfamily, involved in different immunological mechanisms. In the present study, we determined 90K serum levels by a sandwich enzyme immunoassay using the same monoclonal antibody in 11 chronic active hepatitis (CAH), 48 liver cirrhosis and 36 hepatocellular carcinoma (HCC). In comparison, the same samples were also tested for AFP. According to a cut-off point of 14 μg/mL for the 90K, established as 100% of specificity in 50 controls, we observed increasing positivities from CAH to cirrhosis and then to HCC (27%, 50% and 78%, respectively). In cirrhotic patients 90K levels were associated with the presence of anti-HCV antibodies, but not with the degree of liver compromise. Finally, 90K sensitivity was higher than AIFP in all groups of hepatic patients. However, further investigations are needed before proposing 90K as a clinical useful tumour marker in the progression from cirrhosis to HCC.

KW - 90K

KW - Alpha-fetoprotein

KW - Hepatocellular carcinoma

KW - Tumour markers

UR - http://www.scopus.com/inward/record.url?scp=0033428463&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033428463&partnerID=8YFLogxK

M3 - Article

C2 - 10629637

AN - SCOPUS:0033428463

VL - 19

SP - 3469

EP - 3472

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 4 C

ER -